EFSA and ECHA assessment of glyphosate to be pushed back to mid-2023

The European Chemicals Agency (ECHA) and the European Food and Safety Authority (EFSA) announced on May 10, 2022, that an ongoing assessment of the health and environmental risks of glyphosate will be delayed. Glyphosate-based herbicides are the most widely used weedkiller in agriculture.

Under EU Regulation 1107/2009, concerning the placing of plant protection products on the market, active substances must secure approval from the European institutions before they can be used in plant protection products. Said approval is limited in duration  to a maximum of 10 years, although it can be renewed if requested. Both the initial approval and subsequent renewals are decided upon after a process where the Member States and the European Food and Safety Authority review the existing evidence on the substance’s health and environmental impacts.

Currently, glyphosate is undergoing procedures for the renewal of its approval under the plant protection products regulation (for which EFSA is the relevant EU agency), and for its harmonized classification under Regulation 1272/2008, on classification, labelling and packaging of substances and mixtures (handled by ECHA). The current approval for glyphosate under the plant protection products regulation will expire on 15 December 2022. However, the public consultations run by both agencies have seen very high levels of participation which – together with additional information provided by the applicants for the renewal – have added a significant amount of information to the dossier. 

This additional information will be thoroughly considered by the Assessment Group on Glyphosate (AGG), composed of four EU Member States (France, Hungary, the Netherlands, and Sweden). Therefore, EFSA and ECHA are postponing their findings to have enough time to assess the contributions submitted. The revised timeline for the remaining steps in the re-evaluation process and publishing of the assessment is July 2023. 

In light of the above, it is expected that the European Commission will expand the current approval until a decision can be reached based on EFSA’s recommendations.